Topics
Glioblastoma | Treatment | Targeted therapy | Regorafenib
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Regorafenib
Mongiardi MP, Pallini R, D'Alessandris QG, Levi A, Falchetti
ML.
Regorafenib and glioblastoma: a
literature review of preclinical studies, molecular mechanisms and
clinical effectiveness.
Expert
Rev Mol Med. 2024 Apr 2;26:e5. doi:
10.1017/erm.2024.8. PMID:
38563164. Review. ˍ
Berro A, Assi A, Farhat M, Hatoum L, Saad JP, Mohanna R, Bechara
AMA, Prince G, Hachem MCR, Zalaquett Z, Kourie HR.
Unlocking
Hope: Anti-VEGFR inhibitors and their potential in glioblastoma
treatment.
Crit
Rev Oncol Hematol. 2024 Apr 25:104365. doi:
10.1016/j.critrevonc.2024.104365. PMID:
38677355. Review˰
ˍ
**Schettini F, Pineda E, Rocca A, Buché V, Donofrio CA,
Mazariegos M, Ferrari B, Tancredi R, Panni S, Cominetti M, Di
Somma A, González J, Fioravanti A, Venturini S, Generali D.
Identifying the best treatment choice
for relapsing/refractory glioblastoma: a systematic review with
multiple Bayesian network meta-analyses.
Oncologist.
2024 Dec 14:oyae338. doi:
10.1093/oncolo/oyae338. PMID:
39674575. Interventional; Review; Meta-analysis.
ˍ
Mezzari MHDS, Lima NL, Maggi BG, Grüdtner DOM, de Souza JCS,
de Lara LHC, Isolan GR.
Regorafenib in
adult patients with recurrent glioblastoma: a single-arm
meta-analysis.
J
Chemother. 2025 Nov 20:1-12. doi:
10.1080/1120009X.2025.2591474. PMID:
41263675. Meta
analysis˰ ˍ
Wen PY, Berry DA, Buxton MB, Colman H, de Groot J, Lim M,
Mellinghoff I, Perry JR, Weller M, Blondin NA, Butt OH, Damek DM,
de la Fuente MI, Drappatz J, Dunbar E, Giglio P, Hyddmark EV,
Iwamoto F, Jaeckle KA, Kim L, Kling HM, Lee EQ, Mantica M,
Mikkelsen T, Nabors B, Newton HB, Olson JJ, Schiff D, Walbert T,
Weathers SP, Cloughesy T, Lassman AB; GBM AGILE Regorafenib Study
Group.
Evaluation of Regorafenib in
Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III
Bayesian Randomized Platform Trial.
J
Clin Oncol. 2026 Apr 14:JCO2501137. doi:
10.1200/JCO-25-01137. PMID:
41980234. Trial
registration ID: NCT03970447. ˍ